Arthur L Brody1, Kyoji Okita2, Jennifer Shieh3, Lidia Liang3, Robert Hubert3, Michael Mamoun3, Judah Farahi4, Mark A Mandelkern5. 1. Department of Research, VA Greater Los Angeles Healthcare System (VAGLAHS), 11301 Wilshire Blvd., Los Angeles, CA 90073; Department of Psychiatry, University of California at Los Angeles, 300 UCLA Medical Plaza, Suite 2200, Los Angeles, CA 90095. Electronic address: abrody@ucla.edu. 2. Department of Research, VA Greater Los Angeles Healthcare System (VAGLAHS), 11301 Wilshire Blvd., Los Angeles, CA 90073; UCLA Laboratory of Molecular Imaging, 760 Westwood Plaza C8-538, Los Angeles, CA 90095. 3. Department of Research, VA Greater Los Angeles Healthcare System (VAGLAHS), 11301 Wilshire Blvd., Los Angeles, CA 90073. 4. Department of Imaging, VAGLAHS, 11301 Wilshire Blvd., Los Angeles, CA 90073. 5. Department of Imaging, VAGLAHS, 11301 Wilshire Blvd., Los Angeles, CA 90073; Department of Physics, University of California at Irvine, 4129 Frederick Reines Hall, Irvine, CA 92697.
Abstract
INTRODUCTION: When microglia become activated (an integral part of neuroinflammation), cellular morphology changes and expression of translocator protein (TSPO) 18 kDa is increased. Over the past several years, [(11)C]DAA1106 has emerged as a reliable radiotracer for labeling TSPO with high affinity during positron emission tomography (PET) scanning. While [(11)C]DAA1106 PET scanning has been used in several research studies, a radiation dosimetry study of this radiotracer in humans has not yet been published. METHODS: Twelve healthy participants underwent full body dynamic [(11)C]DAA1106 PET scanning, with 8 sequential whole body scans (approximately 12 bed positions each), following a single injection. Regions of interest were drawn manually, and time activity curves (TACs) were obtained for 15 organs. OLINDA/EXM 1.1 was used to compute radiation absorbed doses to the target organs, as well as effective dose (ED) and effective dose equivalent (EDE). RESULTS: The ED and EDE were 4.06 ± 0.58 μSv/MBq and 5.89 ± 0.83 μSv/MBq, respectively. The highest absorbed doses were to the heart wall, kidney, liver, pancreas, and spleen. TACs revealed that peak dose rates are during the first scan (at 6 min) for all organs other than the urinary bladder wall, which had its peak dose rate during the fourth scan (at 30 min). CONCLUSIONS: The recently developed radiotracer [(11)C]DAA1106 has its EDE and target-organ absorbed dose such that, for a single administration, its radiation dosimetry is well within the U.S. FDA guidelines for basic research studies in adults. This dose level implies that the dosimetry for multiple [(11)C]DAA1106 scans within a given year also falls within FDA guidelines, and this favorable property makes this radiotracer suitable for examining microglial activation repeatedly over time, which may in the future be useful for longitudinal tracking of disease progression and monitoring of therapy response in conditions marked by neuroinflammation (e.g., head trauma and multiple sclerosis). Published by Elsevier Inc.
INTRODUCTION: When microglia become activated (an integral part of neuroinflammation), cellular morphology changes and expression of translocator protein (TSPO) 18 kDa is increased. Over the past several years, [(11)C]DAA1106 has emerged as a reliable radiotracer for labeling TSPO with high affinity during positron emission tomography (PET) scanning. While [(11)C]DAA1106 PET scanning has been used in several research studies, a radiation dosimetry study of this radiotracer in humans has not yet been published. METHODS: Twelve healthy participants underwent full body dynamic [(11)C]DAA1106 PET scanning, with 8 sequential whole body scans (approximately 12 bed positions each), following a single injection. Regions of interest were drawn manually, and time activity curves (TACs) were obtained for 15 organs. OLINDA/EXM 1.1 was used to compute radiation absorbed doses to the target organs, as well as effective dose (ED) and effective dose equivalent (EDE). RESULTS: The ED and EDE were 4.06 ± 0.58 μSv/MBq and 5.89 ± 0.83 μSv/MBq, respectively. The highest absorbed doses were to the heart wall, kidney, liver, pancreas, and spleen. TACs revealed that peak dose rates are during the first scan (at 6 min) for all organs other than the urinary bladder wall, which had its peak dose rate during the fourth scan (at 30 min). CONCLUSIONS: The recently developed radiotracer [(11)C]DAA1106 has its EDE and target-organ absorbed dose such that, for a single administration, its radiation dosimetry is well within the U.S. FDA guidelines for basic research studies in adults. This dose level implies that the dosimetry for multiple [(11)C]DAA1106 scans within a given year also falls within FDA guidelines, and this favorable property makes this radiotracer suitable for examining microglial activation repeatedly over time, which may in the future be useful for longitudinal tracking of disease progression and monitoring of therapy response in conditions marked by neuroinflammation (e.g., head trauma and multiple sclerosis). Published by Elsevier Inc.
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Alie Schuitemaker; Marc A Kropholler; Ronald Boellaard; Wiesje M van der Flier; Reina W Kloet; Thalia F van der Doef; Dirk L Knol; Albert D Windhorst; Gert Luurtsema; Frederik Barkhof; Cees Jonker; Adriaan A Lammertsma; Philip Scheltens; Bart N M van Berckel Journal: Neurobiol Aging Date: 2012-07-26 Impact factor: 4.673
Authors: Balázs Gulyás; Boglárka Makkai; Péter Kása; Károly Gulya; Lidia Bakota; Szilvia Várszegi; Zsuzsa Beliczai; Jan Andersson; László Csiba; Andrea Thiele; Thomas Dyrks; Tetsua Suhara; Kazutoshi Suzuki; Makato Higuchi; Christer Halldin Journal: Neurochem Int Date: 2008-10-15 Impact factor: 3.921
Authors: Katrin C Probst; David Izquierdo; Joseph L E Bird; Laurent Brichard; Dominic Franck; John R Davies; Tim D Fryer; Hugh K Richards; John C Clark; Anthony P Davenport; Peter L Weissberg; Elizabeth A Warburton Journal: Nucl Med Biol Date: 2007-05 Impact factor: 2.408
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Sriram Venneti; Brian J Lopresti; Guoji Wang; Susan L Slagel; N Scott Mason; Chester A Mathis; Michelle L Fischer; Niccole J Larsen; Amanda D Mortimer; Teresa G Hastings; Amanda D Smith; Michael J Zigmond; Tetsuya Suhara; Makoto Higuchi; Clayton A Wiley Journal: J Neurochem Date: 2007-06-07 Impact factor: 5.372
Authors: Catherine A Foss; Liansheng Liu; Ronnie C Mease; Haofan Wang; Pankaj Pasricha; Martin G Pomper Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Arthur L Brody; Daniel Gehlbach; Lizette Y Garcia; Ryutaro Enoki; Carl Hoh; David Vera; Kishore K Kotta; Edythe D London; Kyoji Okita; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern Journal: Psychopharmacology (Berl) Date: 2018-10-20 Impact factor: 4.530